



The Company Announcements Platform
ASX Limited
By E-lodgment

Shortfall Placement Oversubscribed

12 July 2016, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise that the shortfall from the recent entitlement offer has been successfully placed, raising additional gross proceeds of approximately \$1.3 million. The shortfall placement was heavily oversubscribed.

The shortfall placement comprised approximately 15 million shares at 9.0 cents per share, together with 1 attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The proceeds from the recent placement and entitlement offer now totals \$10.4 million, before costs.

PTX's CEO, Steven Yatomi-Clarke said, "The interest that PTX continues to receive from a broad audience of investors is excellent, and defies broader market volatility. As the story is becoming progressively discovered, the quality and potential of our programs are steadily becoming recognized."

PTX Chairman, Steven Engle said, "Once again, this is an outstanding response from investors, and we welcome our new investors to the Company ahead of this exciting time for PTX."

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.



PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440